Nevada gives final approval for marijuana consumption lounges

Source: MJBizDaily.com | Author: MJ Biz Daily | June 29, 2022

Nevada regulators have finally finalized rules that open up the state’s cannabis market to an estimated 60-65 marijuana consumption lounges, a move long desired by an industry eager to take better advantage of the state’s bustling tourism industry.

The first marijuana consumption lounges are expected to open before year-end, according to a Cannabis Compliance Board news release promoted on social media.

The regulatory board approved the regulations Tuesday, a year after lawmakers passed a bill permitting the lounges, and after 15 public meetings and workshops on the issue.

Roughly 40-45 licenses would be issued for lounges attached to existing marijuana stores and another 20 for independent lounges, according to the Nevada Independent.

Ten of those licenses would have discounted fees for social equity applicants, the Independent reported, or individuals with a nonviolent marijuana conviction and who live in a designated disadvantaged area.

One of the criticisms of the rules is a high barrier to entry: Applicants must prove they have $200,000 in liquid assets to qualify for license.

“It (the approval of the regulations) has to be viewed as the first step. It’s not going to be perfect,” Tyler Klimas, executive director of the Cannabis Control Board, told the Independent on Monday before the final vote.

The next step is to educate potential applicants about the process through live webinars, tutorials and other resources, according to the Cannabis Control Board news release.

Regulators are expected to open the application process this fall.

Klimas told the Independent he believes some cannabis consumption lounges could open before year-end, given that some stores already have built facilities in hopes of receiving consumption licenses.

The 2022 MJBizFactbook projects that Nevada recreational marijuana sales will reach $900 million-$1.1 billion this year.

Cannabis sales in Nevada hit $1 billion for the fiscal year ended June 30, 2021, according to state data.

Colombia’s turn away from prohibition of cannabis will boost the hemp sector

Source: HempToday.net| Author: Hemp Today | June 24, 2021

In a sharp turn from prohibition-based policy, Colombia will look to advantage small cannabis producers and farming cooperatives, according to a government plan under recently elected President Gustavo Petro.

Petro, a former rebel in the M-19 guerrilla group and a longtime legislator, won Colombia’s presidential election last Sunday, cheering hemp and marijuana interests who hope the new president can execute a plan to transition the country from a narco-state through more constructive policies towards cannabis, coca and poppy.

According to the plan: “The cannabis value chain will receive a special boost, in the hands of producers, linking industry and knowledge, as well as the diversification of uses in the field of medicine, textiles and food, among others.”

The strategy is a fundamental shift in the fight against illegal economies that will position Colombia as a cannabis-producing power through avant-garde policies that take advantage of everything the plant offers, the plan suggests.

Export potential

Envisioning an enhanced framework that favors producer families and co-ops through special permitting privileges and technical support intended to boost farming fortunes while also generating tax revenue for the state, the plan calls for clear regulations, robust research and the promotion of cannabis-based products through cooperation among the state, private sector operators and communities.

“In turn, spaces will be opened in international trade with a variety of (cannabis-) derived products,” according to the 54-page plan, which addresses the broader Colombian economy and society.

Rejecting past policies on drugs rooted in criminalization, the plan notes that “The focus on prohibition in dealing with the global drug problem imposed a war on Colombia around the illegal economies of coca, poppy and cannabis.”

‘War has failed’

“This war has failed and the country needs to move towards a new paradigm that brings together global and Latin American will towards a concerted international agenda based on human rights and the construction of peace, the economic transformation of the productive environments without criminalization of growers, the protection of nature, regulation, the judicial submission of criminal organizations and the approach of consumption as a public health issue,” the plan further observes.

Colombia enacted a law late last year that separated low-THC cannabis from medical marijuana and officially cleared industrial hemp from the country’s drug list. That was followed in February by regulations that set a two-tier system for maximum THC levels, with the limit for grain and fiber crops at 0.3%, while production of flowers, commonly processed for CBD, came under a 1.0% THC barrier.

Potential in CBD

The 1.0% THC limit for hemp flowers should facilitate Colombia’s CBD sector because CBD in hemp plants rises in proportion to THC. A growing number of Latin American and Asian countries are moving to the 1.0% barrier from the generally observed global limit of 0.3%, giving them efficiencies in CBD production.

Colombia also earlier this year put in place international trade regulations for medical marijuana, CBD and other cannabinoids to expand exports.

The Petro government’s development strategy also pledges to move away from over-reliance on fossil fuels, ban aerial spraying of exfoliants such as glyphosate, expand social programs, and more aggressively tax the wealthy.

EIHA says its CBD research will satisfy EU food safety agency’s requirements

Source: HempToday.net | Author: Hemp Today | June 22, 2022

EIHA projects GmbH, a consortium of the European Industrial Hemp Association (EIHA), said research it is currently conducting on the safety of CBD will meet the expectations of the European Food Safety Authority (EFSA).

Concern about safety on the part of EFSA “is definitely not a surprise and 100% in line with our approach,” EIHA said in a statement.

EFSA earlier this month said it had identified gaps in research regarding the effects of CBD on humans, declaring “the safety of CBD as a novel (new) food cannot currently be established.”

The EIHA consortium is spending €2.5 to €3 million on extensive toxicology and clinical research regarding CBD and THC which will be the basis for its novel food applications, which cover isolates and full-spectrum formulations.

Pooling resources

“We decided in 2021 to pool the resources of more than 100 companies and work . . . on a serious and solid submission, anticipating the scientific gaps indicated by EFSA,” EIHA said.

While EFSA has not concluded that CBD consumption is dangerous, the agency said in a statement issued earlier this month that research currently available on the compound’s effects on the liver, gastrointestinal tract, endocrine system, nervous system, and on psychological well-being is insufficient.

The EFSA statement was a response to the European Commission, which sought input from the agency’s experts regarding the safety of CBD. The Commission has said CBD can be classified as a new or “novel” food if it meets relevant provisions in EU food legislation.

Cutting costs

EIHA formed the consortium as a way to reduce the cost of the EU’s novel food approval procedure to its members. The Association estimates the cost of getting a single product approved under novel food rules as ranging from €350,000 to €500,000 per product.

Participation in the EIHA consortium, structured in two categories, significantly reduces those costs. In the first category, producers of hemp biomass and raw materials, makers of processed extracts, premixes, oils, and isolates as well as service providers pay fees according to an eight-tier payment structure which ranges from €20,000 for those with CBD-related income of €1 million or less, up to €330,000 for those with income of €50 million or more. Consortium participants are also required to join the EIHA on a parallel rate scale that ranges from €2,500 to €25,000.

Under a companion 12-tier sublicensing program for white-label operators, fees range from €1,800 for companies with income of €10,000 or less up to €405,000 for those with income of €50 million or more.

Novel food in the EU

Europe’s novel food rules were created to control new, genetically or synthetically produced food products before market entry. Under the guidelines, novel foods are defined as those that were not consumed to a significant degree in the EU before May 15, 1997. If a food is considered novel it must undergo a pre-market safety assessment under EFSA before it can be legally marketed in the EU.

ChemSafe, an Italian consultancy that has experience in the chemical, pharmaceutical, biocides, agrochemical, cosmetics, medical devices and food sectors, is heading the science-based analysis of CBD and THC on behalf of EIHA.

EFSA has scheduled an information session June 28, during which agency representatives will answer questions and provide guidance to current novel food applicants regarding the research gaps identified. A total of 19 CBD applications are now before the agency.

Apple Secretly Joined Amazon In Advancing Commercial Cannabis Reform

Source: Forbes.com | Author: Robert Hoban | Feb 15, 2022

This past summer, a little recognized thing occurred — one of the largest and most respected companies in the world quietly changed its policies in favor of cannabis. That company was Apple. As a result, they joined the ranks of Amazon as a global corporation advocating for policy reform that would open a federally legal, commercial cannabis industry in the United States.

For years, large tech companies, including Facebook and Google, have refused to acknowledge the legality of industrial hemp, let alone the legality of medical or recreational marijuana. Finally, Apple bucked that trend. In June, the fine print of Apple’s “App Store Review Guidelines” release stated that apps handling sales and delivery of medical and recreational cannabis in legal jurisdictions are now allowed on the App Store. This was monumental.  

Unlike the big headlines we’ve seen recently from Amazon, Uber, the NFL, and other mainstream, institutional businesses, showing a positively changing attitude toward cannabis, Apple made no big-splash announcement that this had happened. Yet, this change came at a time of a shift in the cannabis paradigm for voters, policymakers, and the average American. 

As we’ve discussed previously, U.S. voters are shifting rapidly and dramatically in favor of cannabis legalization. The most recent Gallup poll showed that 68% of American voters support some form of legalization. There’s also tremendous momentum from the recent unveiling of the Cannabis Administration and Opportunity Act by Senate Majority Leader Chuck Schumer (D-NY), Senate Finance Committee Chairman Ron Wyden (D-OR) and Sen. Cory Booker (D-NJ).

The financial technology experts at ArtisIQ are ahead of the curve in identifying the imperative to collaborate with tech leaders like Apple to update policy to reflect the mainstream adoption of cannabis. Co-Founder and CMO of Artis, Adair Lion shares, “As a fintech company on the cutting-edge of development in both cannabis and retail, Apple’s Policy changes are a monumental shift in the way our society does mobile transactions.”

When political leaders and Fortune 100 companies begin modifying policies and behavior to accommodate something that has been seen as fringe, elicit, or otherwise illegal, the hearts and minds of American start to change. It’s safe to say the tide is turning. 

This is the kind of influence that sets the tone for mainstream behavior. Think back to the early days of Babe Ruth and baseball, where ball players were smoking cigarettes in the dugout and cigarette advertisements abounded. Or more recently, Elon Musk and Tesla’s support of cryptocurrency which influenced much wider adoption and made the price of Bitcoin soar. 

The fine print of Apple’s policy update states that apps involved in the sale of cannabis are exclusive to licensed legal entities and strictly require geo-fencing within the legal jurisdiction. This requires an enormous amount of technological and regulatory compliance and is precisely where a fintech software company like Artis could excel. Consumer behavior shows the need for embedded digital payment technology. There’s been modest growth in payment and technology solutions for the cannabis industry and ancillary service providers. This is in no small part due to federal illegality and the fragmented nature of the industry.   

Apple’s policy adjustments are just an example of the level of innovation and attention to detail that Artis is providing to the cannabis industry. What is it that propels some tech companies above the rest? It’s those that provide solutions for the world’s most complex problems. It’s plain to see that cannabis has presented enormous complexity to politicians, enterprise businesses, and just about every other imaginable cog in the machine of our modern world.  

The contributions of experienced professionals are unequivocally what is necessary to propel cannabis further into the mainstream. These are the building blocks, the intimate details, that ultimately bring to reality the hopes of grand legislation, like the Cannabis Administration and Opportunity Act. Compliant and lawful participation in the cannabis ecosystem is paramount to widespread, mainstream adoption. As one who has had to navigate the grey areas of cannabis law for many years – and I’m as honest as a Denver man can be – I will always applaud the hard work to deliberately pave the way forward for this industry.

Another bill to raise U.S. THC limit to 1.0% introduced in Congress

Source: HempToday.com | Author: HempToday | Feb 8, 2022

A new bill introduced in the U.S. Congress would raise the limit for THC in hemp from 0.3% to 1.0% and adjust other provisions in current law to ease the path to market for producers.

The Hemp Advancement Act of 2022, introduced by Rep. Chellie Pingree, a Maine Democrat, addresses issues arising from the 2018 Farm Bill, which legalized industrial hemp federally.

In addition to raising the THC limit for crops in the field, provisions in the bill aimed at protecting consumers would set the combined limit for delta-9 and other forms of THC in hemp products at 0.3%.

Raising the limit to 1.0% THC in the field would protect farmers from their crops going hot, and protect producers from hemp going over that limit during the production process, which now makes them technically illegal.

Other key provisions

Other proposed provisions would provide additional protections for the processing and transportation of “hot” hemp, end a Drug Enforcement Agency monopoly on registering testing laboratories, and repeal a controversial ban on drug felons obtaining hemp licenses. 

Under current rules in the Farm Bill, hemp growers and processors often struggle to navigate THC testing and transportation requirements. Meanwhile, consumers are often confused by products that are marketed as hemp but which are more appropriately sold in recreational marijuana sales channels.

U.S. Sen. Rand Paul of Kentucky has twice introduced a separate measure, the Hemp Economic Mobilization Plan Act, which also includes a proposal to raise the THC limit to 1.0%. The U.S. National Association of State Departments of Agriculture has supported the change.

PepsiCo’s new US hemp drink aimed at younger, female customers

Source: HempIndustryDaily.com | Author: Hemp Industry Daily | Feb 2, 2022

PepsiCo has younger female consumers in mind with the U.S. launch of hempseed-infused energy drinks.

Rockstar Energy, a drinks brand owned by PepsiCo, says its three flavors of Rockstar Unplugged with hempseed are aimed at younger females who don’t gravitate toward energy drinks as commonly as males.

The drinks launched nationwide Tuesday and retail for $1.99 for a 12-ounce can, the company said. They contain no cannabinoids.

“Ninety-one percent of our consumers told us they wanted a beverage that lifts their mood,” said Fabiola Torres, PepsiCo general manager and chief marketing officer of its energy business.

PepsiCo released a line of hemp-infused energy drinks in Germany last year and was pleased with the results.

Last summer, PepsiCo joined its rival Coca-Cola and consumer product goods giants including Kellogg in appealing to U.S. health regulators to get going on regulations to allow over-the-counter CBD.

The letter from the Consumer Brands Association argued that current U.S. policy on CBD “is not working” because CBD is not allowed in foods, drinks and dietary supplements, but such products are nonetheless commonly sold by companies flouting regulations from the U.S. Food and Drug Administration.

PepsiCo planto promote its new hemp drink with a three-concert series in conjunction with MTV’s Unplugged franchise.

CBD might help prime cells against COVID

CBD in therapeutic amounts seem to increase the innate anti-viral system of cells readiness to respond to viral infection

Source: University of Waterloo | Author: A.J. Herrington | Jan 11, 2022

Synthetic cannabidiol, a non-psychoactive compound also found in the cannabis plant, appears to prime the innate immune system of cells, potentially offering protection against pathogens such as SARS-CoV-2.

Researchers found that synthetic cannabidiol (CBD) augments the anti-viral response of cells to three key proteins produced by the SARS-CoV-2 genome – which was, until now, an unknown effect.

The researchers studied these proteins in human kidney cellsboth alone and in combination with CBD, as well as the effects of CBD in healthy control cells.

“When cells in the lungs or the digestive tract are infected with a virus, they have an ability to sense and respond, even before the immune system notices a virus is present,” said Robin Duncan, lead investigator and a professor in the University of Waterloo’s Department of Kinesiology and Health Sciences. “They do this by activating innate responses inside of cells, which form the first line of defence. In the case of COVID-19, however, this response isn’t very good, which has contributed to high infection rates.

“With an RNA-type virus, like SARS-CoV-2, cells should activate an innate system that cuts up the viral genome, which also causes infected cells to undergo a process called apoptosis – a sort of controlled cell death that gets rid of infected cells early on. This could stop an infection, or slow its spread in the body or to others. When we combined CBD with these viral proteins, they had a much better ability to activate this system and to activate apoptosis.”

Duncan said what was potentially even more exciting, however, was that in cells that had not been exposed to the SARS-CoV-2 proteins, CBD in therapeutic amounts seemed to prime the innate anti-viral system of cells, increasing their readiness to respond to viral infection – and that this happened without activating apoptosis in healthy cells.

Waterloo’s postdoctoral fellow Maria Fernandes, who performed the cell studies, said, “This suggests CBD at the right dose could help cells be in a better state of readiness to respond to a virus, but it doesn’t cause a response unless there is a need.”

Duncan said this idea is supported by evidence from users of a high-dose pharmaceutical CBD licensed in the United States for the treatment of rare types of epilepsy. In that study, patients taking prescription high-dose CBD had around a 10-fold lower risk of testing positive for COVID-19.

Duncan points out that CBD does not cause a high, the way THC does, making it more widely useful.

The study, “Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein,” is co-authored by Duncan, Fernandes, John Zewen Chan, Chia Chun Joey Hung and Michelle Tomczewski. A pre-peer-reviewed version is published on BioRxiv.org, and is under review in the journal Life Sciences.

The researchers said the discovery of this study is not meant to replace practices that are known to work in reducing the spread of COVID-19, such as masking, vaccination and other measures recommended by health experts.

Study Finds Cannabis Compounds Prevent Infection By Covid-19 Virus

Source: Forbes.com | Author: A.J. Herrington | Jan 11, 2022

Compounds in cannabis can prevent infection from the virus that causes Covid-19 by blocking its entry into cells, according to a study published this week by researchers affiliated with Oregon State University. A report on the research, “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants,” was published online on Monday by the Journal of Natural Products.

The researchers found that two cannabinoid acids commonly found in hemp varietals of cannabis, cannabigerolic acid, or CBGA, and cannabidiolic acid, also known as CBDA, can bind to the spike protein of SARS-CoV-2, the virus that causes Covid-19. By binding to the spike protein, the compounds can prevent the virus from entering cells and causing infection, potentially offering new avenues to prevent and treat the disease.

“Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2,” the researchers wrote in an abstract of the study.

The study was led by Richard van Breemen, a researcher with Oregon State’s Global Hemp Innovation Center in the College of Pharmacy and Linus Pauling Institute, in collaboration with scientists at the Oregon Health & Science University. Van Breeman said that the cannabinoids studied are common and readily available.

“These cannabinoid acids are abundant in hemp and in many hemp extracts,” van Breemen said, as quoted by local media. “They are not controlled substances like THC, the psychoactive ingredient in marijuana, and have a good safety profile in humans.”

End of article.

Green Sugr contains all cannabinoids and terpenes making it the most effective legal CBD product in the market worldwide.

Hemp experts say 2023 Farm Bill could even playing field between US and rival countries

Source: HempIndustryDaily.com | Author: Kate Lavin | Oct 21, 2021

Closing the gaps between the 2014 and 2018 Farm Bills could provide U.S. hemp companies with “a leg up on international trade,” according to Joy Beckerman, principal at New York-based Hemp Ace International.

Beckerman spoke Tuesday at the Hemp Industry Daily Forum, a daylong preconference event held in Las Vegas in connection with MJBizCon.

U.S. hemp companies looking to open new international markets may be eligible for government grants and programs to fund costs such as travel, said Larry Farnsworth, senior vice president of communications and marketing for the National Industrial Hemp Council.

Federal funds for such such business-development projects opened to hemp companies when the 2018 Farm Bill legalized the cultivation, processing and sale of hemp and hemp-derived products.

Trouble at home

Disparities between the 2014 and 2018 Farm Bill documents continue to create strife in the United States, however.

Regulators in some hemp markets adhere to rules from the 2014 Farm Bill, while others follow the 2018 document, making “some people think they are at a disadvantage to their neighboring states,” Farnsworth said.

Garrett Graff, partner at Moye White law firm in Denver, said he expects the 2023 Farm Bill to contain more harmonization of the two packages of federal legislation, along with further insight about testing rules required by the U.S. Drug Enforcement Administration.

He also expects environmental, social and corporate governance to play a larger role in the updated Farm Bill.

In the nearer term, NIHC’s Farnsworth predicted the U.S. Senate and House of Representatives would affirm the U.S. Department of Agriculture’s authority over hemp. Meanwhile, Senate Bill 1698, the Hemp Access and Consumer Safety Act, stands to clarify that hemp-derived CBD can be included in dietary supplements and food.

Planning for 2023

For her part, Beckerman would like to see the federally legal plant treated as such going forward.

Additionally, she said the 2023 Farm Bill should make clear that naturally occurring cannabinoids are a part of federally legal hemp, meaning the sale and use of hemp-derived CBD and other cannabinoids in finished products should not be subject to criminal enforcement in the United States.

“We defined a plant in the Farm Bill. We didn’t define a finished product, but that is what we are dealing with,” she said.

Other key issues Beckerman would like clarified in the 2023 Farm Bill include a repeal of the drug felon ban, which precludes individuals convicted of certain drug crimes from growing hemp for 10 years, and the ability to repurpose hemp that tests above the 0.3% THC limit for construction materials, plastics and other purposes.

Hemp content at MJBizCon

The Hemp Industry Daily Forum was one of three preconference events held as part of MJBizCon at the Las Vegas Convention Center.

In addition to several dozen educational sessions, MJBizCon includes a trade show with more than 1,000 exhibitors for the cannabis industry. Register for MJBizCon at mjbizconference.com.

Czech change on THC limit sets an example for other EU states

Source: HempToday.net | Author: Hemp Today | Sept 27, 2021

Amendments to Czech law that would raise the national THC limit for industrial hemp to 1.0% could spark other EU countries to revisit their current limits. But the change is not likely to affect farmers, who can’t qualify for subsidies if their hemp crops are over the EU limit of 0.2%, and food and cosmetics rules still must be changed to establish a legal pathway to market for those products.

Czech President Miloš Zeman is expected to sign the bill after the Parliament’s Chamber of Deputies sent it to his desk earlier this month.

Changing the amount of THC allowable in hemp plants to 1.0% would put the Czech limit well beyond that of the EU, even after the European Parliament voted last October to increase the authorized THC level for industrial hemp “on the field” from 0.2% to 0.3%.

Farm subsidies critical

In addition to direct cash offsets, many European farmers growing hemp have depended on direct subsidies or EU Rural Development Programme funds as security for agricultural loans and deferred payments. To be eligible for those funds, farmers’ crops may not go beyond the EU’s 0.2% THC limit despite local laws which may be different.

But the Czech law pushing the THC level beyond the EU limit could nonetheless serve as a beacon to other member states, stakeholders say.

“It’s definitely an interesting signal to other EU countries, and maybe it can eventually help to bring the European THC level to 1.0% in the long run,” said Boris Baňas, Chief Sales Officer at Czech-based CBDepot, who estimated that process could take “more than a year or two.”

While the EU-wide change to 0.3% THC is not expected to be in effect until 2023, member states are now in the process of adjusting their national laws to align with the updated limit after the change was included in the most recent round of Common Agricultural Policy (CAP) reforms.

Trend to 1.0% THC

Many nations around the world are establishing 1.0% THC as their national limits, breaking with the generally accepted global guidance of 0.3% that has been observed since hemp re-emerged in the 1990s.

“Many countries are at 1% already, including Switzerland and Australia,” said veteran American cannabis consultant Richard Rose, who has suggested that certification of hemp varieties should imply legal THC levels. “Not testing THC for approved varieties is what I’ve been advocating for years, since government certification should count for SOMEthing,” Rose said.

The higher limit is important especially for CBD producers; higher THC means higher levels of CBD, as the two compounds rise in proportion. For farmers, it means much less risk of their crops going “hot,” or over the allowable THC level.

“EIHA welcomes this modern approach to THC limits, which is in line with the global development of commercial hemp cultivation,” European Industrial Hemp Association President Daniel Kruse said of the new Czech law.

Decriminalizing extracts

Aside from resetting the THC limit for hemp “on the field,” the new law would mean possession of hemp extracts and tinctures with less than 1% THC won’t be considered a criminal act. “But it doesn’t mean you can infuse any food or cosmetics as such,” Baňas said. Those rules must still be changed to create a legal market.

In a report to Czech Senators outlining the new law, CzecHemp, a stakeholder cluster, said the package of amendments “opens the possibility to manufacture and market products up to a maximum of 1.0% of tetrahydrocannabinol,” but notes that provisions in the new law are “without prejudice to other regulations,” and that products “must be safe and non-misuse.”

While the new law won’t lead to immediate marketability of food and cosmetics, it would decriminalize hemp-based health aids or “cosmetics” often home-made by Czech seniors, according to CzecHemp.

Little effect on processing

While the THC limit change could lead to more latitude and less bureaucracy for extractors, Baňas is skeptical about that. “THC often goes over 1% in hemp processing,” he said. “That means those companies will still need to have authorization for handling that material.”

Under the updated medical cannabis provisions in the new law, multiple licensed private groups could be authorized to manufacture medical cannabis products. Proponents say the changes would expand the availability and diversity of products through competition certain to drive down prices to patients.

In other interpretations from CzecHemp, the new law also:

  • Introduces the term “technical hemp,” (industrial hemp) defined as a plant which comes from seeds listed in the European Catalog or from which hemp with a content of up to 1% THC can be produced.
  • Removes a requirement that processors of “technical cannabis” have authorization to handle addictive substances.
  • Establishes the term “hemp extract for medical use” defined as “intended for the preparation of an individually prepared medicinal product.” CzecHemp said the State Institute for Drug Control must still amend existing legislation to set conditions for “prescribing, preparation, distribution, dispensing and use of individually prepared medicinal products containing cannabis for therapeutic use.”